Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?

Bulletin du Cancer

Volumn 99, Issue 12, 2012, Pages

  Vanhuyse, Marie ^a,b   Penel, Nicolas ^a   Caty, Armelle ^a   Fumagalli, Ingrid ^a   Alt, Marie ^a   Zini, Laurent ^c   Adenis, Antoine ^a,b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Anti angiogenic; Brain; Cancer; Metastasis; Renal; Targeted therapies

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; EVEROLIMUS; GEMCITABINE; INTERFERON; INTERLEUKIN 2; MEDROXYPROGESTERONE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RISK FACTOR;

EID: 84872356586     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1672     Document Type: Article

References (21)

1. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27 : 291-301. (Pubitemid 17050456)
2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30 : 843-52. (Pubitemid 37485197)
3. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161 : 381-6.
4. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94 : 2698-705. (Pubitemid 34478086)
5. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008; 113 : 1641-8.
6. Wrónski M, Maor MH, Davis BJ, Sawaya R, Levin VA. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 1997; 37 : 753-9. (Pubitemid 27181304)
7. Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998; 83 : 344-53. (Pubitemid 28317815)
8. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25 : 2295-305. (Pubitemid 46954658)
9. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 : 3584-90.
10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27 : 3312-8.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370 : 2103-11. (Pubitemid 350296300)
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356 : 2271-81. (Pubitemid 46849157)
13. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012; 18 : 2766-77.
14. Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117 : 501-9.
15. Chevreau C, Ravaud A, Escudier B, et al. Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. ASCO 2011. J Clin Oncol 2011; 29: 2011 (Suppl. abs. 4625).
16. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 : 1280-9.
17. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28 : 2144-50.
18. Valcamonico F, Ferrari V, Amoroso V, et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009; 91 : 47-50.
19. Walid MS, Johnston KW. Successful treatment of a brain-metastasized renal cell carcinoma. Ger Med Sci 2009 ; 7 : Doc 28.
20. Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with anti-angiogenic therapy. J Neurooncol 2008; 86 : 243-4. (Pubitemid 350263426)
21. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21 : 1027-31.